Tejkamal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 4.50 Cr
as on 16-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 18.84 Cr
as on 16-12-2024
- Revenue 354.82%
(FY 2020)
- Profit 101.94%
(FY 2020)
- Ebitda 97.68%
(FY 2020)
- Net Worth 0.48%
(FY 2020)
- Total Assets -18.55%
(FY 2020)
About Tejkamal Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.50 Cr.
The company has closed loans amounting to ₹18.84 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vipin Kumar and Deepa Jain serve as directors at the Company.
- CIN/LLPIN
U24231KA2008PTC045112
- Company No.
045112
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tejkamal Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vipin Kumar  | Director | 30-Jan-2008 | Current |
| Deepa Jain | Director | 01-Feb-2021 | Current |
Financial Performance of Tejkamal Pharmaceuticals.
Tejkamal Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 354.82% increase. The company also saw a substantial improvement in profitability, with a 101.94% increase in profit. The company's net worth moved up by a moderate rise of 0.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tejkamal Pharmaceuticals?
In 2020, Tejkamal Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tejkamal Trade Links Private LimitedActive 23 years 1 monthVipin Kumar and Deepa Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 31 Jan 2014 | ₹0.75 M | Satisfied |
Canara Bank Creation Date: 23 Oct 2013 | ₹1.00 M | Satisfied |
Canara Bank Creation Date: 02 Sep 2009 | ₹18.66 Cr | Satisfied |
How Many Employees Work at Tejkamal Pharmaceuticals?
Unlock and access historical data on people associated with Tejkamal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tejkamal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tejkamal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
